{"resourceType":"ImplementationGuide","id":"celida-recommendations","text":{"status":"extensions","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2>CELIDARecommendations</h2><p>The official URL for this implementation guide is: </p><pre>https://www.ceosys.de/fhir/ImplementationGuide/celida-recommendations</pre></div>"},"url":"https://www.ceosys.de/fhir/ImplementationGuide/celida-recommendations","version":"1.0.0-snapshot","name":"CELIDARecommendations","title":"CODEX+ CELIDA Recommendations","status":"draft","date":"2022-09-15T16:17:14+00:00","publisher":"Universitätsmedizin Greifswald","contact":[{"name":"Universitätsmedizin Greifswald","telecom":[{"system":"url","value":"https://www.medizin.uni-greifswald.de/"}]}],"packageId":"celida-recommendations","license":"CC0-1.0","fhirVersion":["5.0.0-ballot"],"dependsOn":[{"id":"hl7_terminology","uri":"http://terminology.hl7.org/ImplementationGuide/hl7.terminology","packageId":"hl7.terminology","version":"3.1.0"},{"id":"cpg_ceosys_de","uri":"https://www.ceosys.de/fhir/ImplementationGuide/cpg.ceosys.de","packageId":"cpg.ceosys.de","version":"0.3.1-snapshot"}],"definition":{"resource":[{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"PlanDefinition"}],"reference":{"reference":"PlanDefinition/AbdominalPositioningARDSPlan"},"name":"Abdominal positioning plan in case of ARDS and a PaO2/FiO2 < 150 mmHg,","description":"In ARDS and a PaO2/FiO2 < 150 mmHg, abdominal positioning should be consistently performed, with an abdominal positioning interval of at least 16 hours. ","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"PlanDefinition"}],"reference":{"reference":"PlanDefinition/AntithrombFondapProphInHospitalisedCOVID19PatientsRecommPlan"},"name":"Antithrombotic prophylaxis with Fondaparinux","description":"Antithrombotic prophylaxis with Fondaparinux in hospitalised COVID-19 patients","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"PlanDefinition"}],"reference":{"reference":"PlanDefinition/AntithrombLWMHProphInHospitalisedCOVID19PatientsRecommPlan"},"name":"Antithrombotic prophylaxis with LWMH","description":"Hospitalized patients with COVID-19 should receive standard drug thromboembolism prophylaxis with low molecular weight heparin in the absence of contraindications. Alternatively, fondaparinux may be used. ","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/AntithromboticProphylaxisFondaparinuxSubcutaneous"},"name":"Antithrombotic prophylaxis with Fondaparinux","description":"Antithrombotic prophylaxis with Fondaparinux in hospitalised COVID-19 patients (when contraindications for LWMH exist)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"PlanDefinition"}],"reference":{"reference":"PlanDefinition/NoAntithrombProphInHospitalisedCOVID19PatientsRecommPlan"},"name":"No antithrombotic prophylaxis in patients with thrombosis","description":"No antithrombotic prophylaxis in patients with thrombosis","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/NoAntithromboticProphylaxisFondaparinuxSubcutaneous"},"name":"Antithrombotic prophylaxis with Fondaparinux","description":"Antithrombotic prophylaxis with Fondaparinux in hospitalised COVID-19 patients (when contraindications for LWMH exist)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/NoProphylacticAnticoagulationWCertoparin"},"name":"Antithrombotic prophylaxis with with Certoparin","description":"Antithrombotic prophylaxis with Certoparin in hospitalised COVID-19 patients (in absence of contraindications for LWMH)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/NoProphylacticAnticoagulationWDalteparin"},"name":"Antithrombotic prophylaxis with Dalteparin","description":"Antithrombotic prophylaxis with Dalteparin in hospitalised COVID-19 patients (in absence of contraindications for LWMH)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/NoProphylacticAnticoagulationWEnoxaparin"},"name":"Antithrombotic prophylaxis with Enoxaparin","description":"Antithrombotic prophylaxis with Enoxaparin in hospitalised COVID-19 patients (in absence of contraindications for LWMH)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/NoProphylacticAnticoagulationWNadroparinHighWeight"},"name":"Antithrombotic prophylaxis with Nadroparin High Weight","description":"Antithrombotic prophylaxis with Nadroparin High Weight in hospitalised COVID-19 patients (in absence of contraindications for LWMH)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/NoProphylacticAnticoagulationWNadroparinLowWeight"},"name":"Antithrombotic prophylaxis with Nadroparin Low Weight","description":"Antithrombotic prophylaxis with Nadroparin Low Weight in hospitalised COVID-19 patients (in absence of contraindications for LWMH)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"PlanDefinition"}],"reference":{"reference":"PlanDefinition/NoTherapeuticAnticoagulationICUCOVID19NoIndicationPlan"},"name":"Anticoagulation Plan for hospitalized intensive-care COVID-19 patients with no specific indication","description":"In intensive care patients without a specific indication (e.g. pulmonary embolism), therapeutic anticoagulation should not be given.","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/NoTherapeuticAnticoagulationWArgatra"},"name":"No Therapeutic Anticoagulation Treatment with Argatroban","description":"No Therapeutic Anticoagulation Treatment with Argatroban for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/NoTherapeuticAnticoagulationWCertoparin"},"name":"No Therapeutic Anticoagulation Treatment with Certoparin","description":"No Therapeutic Anticoagulation Treatment with Certoparin for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/NoTherapeuticAnticoagulationWDalteparin"},"name":"No Therapeutic Anticoagulation Treatment with Dalteparin","description":"No Therapeutic Anticoagulation Treatment with Dalteparin for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/NoTherapeuticAnticoagulationWEnoxaparin"},"name":"No Therapeutic Anticoagulation Treatment with Enoxaparin","description":"No Therapeutic Anticoagulation Treatment with Enoxaparin for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/NoTherapeuticAnticoagulationWNadroparinHighWeight"},"name":"No Therapeutic Anticoagulation Treatment with Nadroparin High Weight","description":"No Therapeutic Anticoagulation Treatment with Nadroparin for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/NoTherapeuticAnticoagulationWNadroparinLowWeight"},"name":"No Therapeutic Anticoagulation Treatment with Nadroparin Low Weight","description":"No Therapeutic Anticoagulation Treatment with Nadroparin for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/NoTherapeuticAnticoagulationWUFH"},"name":"No Therapeutic Anticoagulation Treatment with UFH","description":"No Therapeutic Anticoagulation Treatment with UFH for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"EvidenceVariable"}],"reference":{"reference":"EvidenceVariable/PopHospitalisedCOVID19PatientsWITHThrombosis"},"name":"Population: Hospitalised COVID-19 Patients with (venous) thrombosis","description":"Population for recommendation 15: Hospitalised COVID-19 Patients with (venous) thrombosis","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"EvidenceVariable"}],"reference":{"reference":"EvidenceVariable/PopHospitalisedCOVID19PatientsWOVenousThrombosisWITHCI"},"name":"Population: Hospitalised COVID-19 patients without (venous) thrombosis, existing contraindications to LWMH","description":"Population for recommendation 15: Hospitalised COVID-19 patients without (venous) thrombosis, existing contraindications to LWMH","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"EvidenceVariable"}],"reference":{"reference":"EvidenceVariable/PopHospitalisedCOVID19PatientsWOVenousThrombosisWOCI"},"name":"Population: Hospitalised COVID-19 patients without (venous) thrombosis and without contraindications to LWMH","description":"Population for recommendation 15: Hospitalised COVID-19 patients without (venous) thrombosis and without contraindications to LWMH","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"EvidenceVariable"}],"reference":{"reference":"EvidenceVariable/PopHospitalisedICUCOVID19Patients"},"name":"Hospitalised COVID-19 patients, treated on ICU, without thrombembolic complication","description":"Hospitalised COVID-19 patients, treated on ICU, without thrombembolic complication","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"EvidenceVariable"}],"reference":{"reference":"EvidenceVariable/PopHospitalisedNonICUCOVID19PatientsWOThrombosisWITHHighRisk"},"name":"Population: Rec17EK, Hospitalised COVID-19 patients without the need for intensive care therapy, without venous thrombosis, considered high-risk for developing venous thrombosis","description":"Population for recommendation 17 from guideline from https://www.awmf.org/leitlinien/detail/ll/113-001LG.html with characteristics: without the need for intensive care therapy, without venous thrombosis, considered high-risk for developing venous thrombosis","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"EvidenceVariable"}],"reference":{"reference":"EvidenceVariable/PopVentilatedCOVID19patientsWithARDSWithOxygenationFailure"},"name":"Population: Ventilated COVID-19 Patients with severe ARDS","description":"Ventilated COVID-19 patients with severe ARDS, defined by oxygenation failure (Horovitz Quotient lower than 150)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"EvidenceVariable"}],"reference":{"reference":"EvidenceVariable/PopulationVentilatedCOVID19patientsWithARDS"},"name":"Population: Ventilated COVID-19 Patients with ARDS","description":"Ventilated COVID-19 patients with ARDS","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"EvidenceVariable"}],"reference":{"reference":"EvidenceVariable/PopulationVentilatedCOVID19patientsWithARDS-fio2-1"},"name":"Population: Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 1.0","description":"Ventilated COVID-19 patients with ARDS, inspiratory oxygen fraction currently 1.0","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"EvidenceVariable"}],"reference":{"reference":"EvidenceVariable/PopulationVentilatedCOVID19patientsWithARDS-fio2-point3"},"name":"Population: Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 0.3","description":"Ventilated COVID-19 patients with ARDS, inspiratory oxygen fraction currently 0.3 - 0.39","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"EvidenceVariable"}],"reference":{"reference":"EvidenceVariable/PopulationVentilatedCOVID19patientsWithARDS-fio2-point4"},"name":"Population: Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 0.4","description":"Ventilated COVID-19 patients with ARDS, inspiratory oxygen fraction currently 0.4 - 0.49","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"EvidenceVariable"}],"reference":{"reference":"EvidenceVariable/PopulationVentilatedCOVID19patientsWithARDS-fio2-point5"},"name":"Population: Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 0.5","description":"Ventilated COVID-19 patients with ARDS, inspiratory oxygen fraction currently 0.5 - 0.59","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"EvidenceVariable"}],"reference":{"reference":"EvidenceVariable/PopulationVentilatedCOVID19patientsWithARDS-fio2-point6"},"name":"Population: Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 0.6","description":"Ventilated COVID-19 patients with ARDS, inspiratory oxygen fraction currently 0.6 - 0.69","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"EvidenceVariable"}],"reference":{"reference":"EvidenceVariable/PopulationVentilatedCOVID19patientsWithARDS-fio2-point7"},"name":"Population: Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 0.7","description":"Ventilated COVID-19 patients with ARDS, inspiratory oxygen fraction currently 0.7 - 0.79","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"EvidenceVariable"}],"reference":{"reference":"EvidenceVariable/PopulationVentilatedCOVID19patientsWithARDS-fio2-point8"},"name":"Population: Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 0.8","description":"Ventilated COVID-19 patients with ARDS, inspiratory oxygen fraction currently 0.8 - 0.89","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"EvidenceVariable"}],"reference":{"reference":"EvidenceVariable/PopulationVentilatedCOVID19patientsWithARDS-fio2-point9"},"name":"Population: Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 0.9","description":"Ventilated COVID-19 patients with ARDS, inspiratory oxygen fraction currently 0.9 - 0.99","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/PronePositioning"},"name":"Abdominal Positioning","description":"In ARDS and a PaO2/FiO2 < 150 mmHg, abdominal positioning should be consistently performed, with an abdominal positioning interval of at least 16 hours.","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/ProphylacticAnticoagulationWCertoparin"},"name":"Antithrombotic prophylaxis with Certoparin","description":"Antithrombotic prophylaxis with Certoparin in hospitalised COVID-19 patients (in absence of contraindications for LWMH)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/ProphylacticAnticoagulationWDalteparin"},"name":"Antithrombotic prophylaxis with Dalteparin","description":"Antithrombotic prophylaxis with Dalteparin in hospitalised COVID-19 patients (in absence of contraindications for LWMH)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/ProphylacticAnticoagulationWEnoxaparin"},"name":"Antithrombotic prophylaxis with Enoxaparin","description":"Antithrombotic prophylaxis with Enoxaparin in hospitalised COVID-19 patients (in absence of contraindications for LWMH)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/ProphylacticAnticoagulationWNadroparinHighWeight"},"name":"Antithrombotic prophylaxis with Nadroparin High Weight","description":"Antithrombotic prophylaxis with Nadroparin High Weight in hospitalised COVID-19 patients (in absence of contraindications for LWMH)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/ProphylacticAnticoagulationWNadroparinLowWeight"},"name":"Antithrombotic prophylaxis with Nadroparin Low Weight","description":"Antithrombotic prophylaxis with Nadroparin Low Weight in hospitalised COVID-19 patients (in absence of contraindications for LWMH)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/TherapeuticAnticoagulationFondaparinux"},"name":"Therapeutic Anticoagulation Treatment with Fondaparinux","description":"Therapeutic Anticoagulation Treatment with Fondaparinux for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/TherapeuticAnticoagulationNMHCertoparin"},"name":"Therapeutic Anticoagulation Treatment with Certoparin","description":"Therapeutic Anticoagulation Treatment (NMH) for non-intensive care hospitalised COVID-19 patients patients with high risk (D-Dimer >= 2mg/l) with Certoparin","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/TherapeuticAnticoagulationNMHDalteparin"},"name":"Therapeutic Anticoagulation Treatment with Dalteparin","description":"Therapeutic Anticoagulation Treatment (NMH) for non-intensive care hospitalised COVID-19 patients patients with high risk (D-Dimer >= 2mg/l) with Dalteparin","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/TherapeuticAnticoagulationNMHEnoxaparin"},"name":"Therapeutic Anticoagulation Treatment with Enoxaparin","description":"Therapeutic Anticoagulation Treatment (NMH) for non-intensive care hospitalised COVID-19 patients patients with high risk (D-Dimer >= 2mg/l) with Enoxaparin","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/TherapeuticAnticoagulationNMHNadroparinHighWeight"},"name":"Therapeutic Anticoagulation Treatment with Nadroparin High Weight","description":"Therapeutic Anticoagulation Treatment (NMH) for non-intensive care hospitalised COVID-19 patients (high weight) with high risk (D-Dimer >= 2mg/l) with Nadroparin","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/TherapeuticAnticoagulationNMHNadroparinLowWeight"},"name":"Therapeutic Anticoagulation Treatment with Nadroparin Low Weight","description":"Therapeutic Anticoagulation Treatment (NMH) for non-intensive care hospitalised COVID-19 patients (low weight) with high risk (D-Dimer >= 2mg/l) with Nadroparin","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"PlanDefinition"}],"reference":{"reference":"PlanDefinition/TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan"},"name":"Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients with no renal function impairment (eGFR >= 30ml/min))","description":"In hospitalized, non-intensive care patients with COVID-19 and increased risk (e.g., D-dimers ≥ 2 mg/l), therapeutic anticoagulation can be considered if the risk of bleeding is low. Anticoagulation, preferentially with NMH or UFH, can be considered.","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/TherapeuticAnticoagulationUFH"},"name":"Therapeutic Anticoagulation Treatment UFH","description":"Therapeutic Anticoagulation Treatment (UFH) for non-intensive care hospitalised COVID-19 patients patients with high risk (D-Dimer >= 2mg/l)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"ActivityDefinition"}],"reference":{"reference":"ActivityDefinition/TherapeuticAnticoagulationWArgatra"},"name":"Therapeutic Anticoagulation Treatment with Argatroban","description":"Therapeutic Anticoagulation Treatment with Argatroban for non-intensive care hospitalised COVID-19 patients patients with no specific indications (i.e., pulmonary embolism)","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"PlanDefinition"}],"reference":{"reference":"PlanDefinition/VentilatedCOVID19PatientsWithARDSVentilationPlan"},"name":"Ventilation Plan for COVID-19 patients with ARDS","description":"In ventilated patients with COVID-19 and ARDS, tidal volume should be ≤ 6 ml/kg standard body weight, end-inspiratory airway pressure ≤ 30 cm H2O.","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"PlanDefinition"}],"reference":{"reference":"PlanDefinition/VentilatedCOVID19patientsWithARDSInterventionPlan-fio2-1"},"name":"PEEP Intervention Plan for Population: Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 1.0","description":"PEEP Intervention Plan for Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 1.0 - 1.09","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"PlanDefinition"}],"reference":{"reference":"PlanDefinition/VentilatedCOVID19patientsWithARDSInterventionPlan-fio2-point3"},"name":"PEEP Intervention Plan for Population: Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 0.3","description":"PEEP Intervention Plan for Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 0.3 - 0.39","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"PlanDefinition"}],"reference":{"reference":"PlanDefinition/VentilatedCOVID19patientsWithARDSInterventionPlan-fio2-point4"},"name":"PEEP Intervention Plan for Population: Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 0.3","description":"PEEP Intervention Plan for Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 0.3 - 0.39","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"PlanDefinition"}],"reference":{"reference":"PlanDefinition/VentilatedCOVID19patientsWithARDSInterventionPlan-fio2-point5"},"name":"PEEP Intervention Plan for Population: Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 0.5","description":"PEEP Intervention Plan for Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 0.5 - 0.59","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"PlanDefinition"}],"reference":{"reference":"PlanDefinition/VentilatedCOVID19patientsWithARDSInterventionPlan-fio2-point6"},"name":"PEEP Intervention Plan for Population: Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 0.6","description":"PEEP Intervention Plan for Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 0.6 - 0.69","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"PlanDefinition"}],"reference":{"reference":"PlanDefinition/VentilatedCOVID19patientsWithARDSInterventionPlan-fio2-point7"},"name":"PEEP Intervention Plan for Population: Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 0.7","description":"PEEP Intervention Plan for Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 0.7 - 0.79","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"PlanDefinition"}],"reference":{"reference":"PlanDefinition/VentilatedCOVID19patientsWithARDSInterventionPlan-fio2-point8"},"name":"PEEP Intervention Plan for Population: Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 0.8","description":"PEEP Intervention Plan for Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 0.8 - 0.89","isExample":true},{"extension":[{"url":"http://hl7.org/fhir/tools/StructureDefinition/resource-information","valueString":"PlanDefinition"}],"reference":{"reference":"PlanDefinition/VentilatedCOVID19patientsWithARDSInterventionPlan-fio2-point9"},"name":"PEEP Intervention Plan for Population: Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 0.9","description":"PEEP Intervention Plan for Ventilated COVID-19 Patients with ARDS, inspiratory oxygen fraction currently 0.9 - 0.99","isExample":true}],"page":{"name":"toc.html","title":"Table of Contents","generation":"html","page":[{"name":"index.html","title":"CELIDA Recommendations","generation":"markdown"},{"name":"downloads.html","title":"Downloads","generation":"html"},{"name":"changelog.html","title":"Change Log","generation":"markdown"}]},"parameter":[{"code":{"code":"copyrightyear"},"value":"2021+"},{"code":{"code":"releaselabel"},"value":"ci-build"},{"code":{"code":"active-tables"},"value":"true"},{"code":{"code":"apply-contact"},"value":"false"},{"code":{"code":"apply-jurisdiction"},"value":"false"},{"code":{"code":"apply-publisher"},"value":"false"},{"code":{"code":"apply-version"},"value":"false"},{"code":{"code":"show-inherited-invariants"},"value":"false"},{"code":{"code":"usage-stats-opt-out"},"value":"true"},{"code":{"code":"excludexml"},"value":"false"},{"code":{"code":"excludejsn"},"value":"false"},{"code":{"code":"excludettl"},"value":"true"},{"code":{"code":"excludemap"},"value":"true"},{"code":{"code":"excludeexample"},"value":"true"},{"code":{"code":"extension-domain"},"value":"https://www.netzwerk-universitaetsmedizin.de"},{"code":{"code":"extension-domain"},"value":"https://simplifier.net"},{"code":{"code":"path-resource"},"value":"input/capabilities"},{"code":{"code":"path-resource"},"value":"input/examples"},{"code":{"code":"path-resource"},"value":"input/extensions"},{"code":{"code":"path-resource"},"value":"input/models"},{"code":{"code":"path-resource"},"value":"input/operations"},{"code":{"code":"path-resource"},"value":"input/profiles"},{"code":{"code":"path-resource"},"value":"input/resources"},{"code":{"code":"path-resource"},"value":"input/vocabulary"},{"code":{"code":"path-resource"},"value":"input/maps"},{"code":{"code":"path-resource"},"value":"input/testing"},{"code":{"code":"path-resource"},"value":"input/history"},{"code":{"code":"path-resource"},"value":"fsh-generated/resources"},{"code":{"code":"path-pages"},"value":"template/config"},{"code":{"code":"path-pages"},"value":"input/images"},{"code":{"code":"path-liquid"},"value":"template/liquid"},{"code":{"code":"path-liquid"},"value":"input/liquid"},{"code":{"code":"path-qa"},"value":"temp/qa"},{"code":{"code":"path-temp"},"value":"temp/pages"},{"code":{"code":"path-output"},"value":"output"},{"code":{"code":"path-tx-cache"},"value":"input-cache/txcache"},{"code":{"code":"path-suppressed-warnings"},"value":"input/ignoreWarnings.txt"},{"code":{"code":"path-history"},"value":"https://www.ceosys.de/fhir/history.html"},{"code":{"code":"template-html"},"value":"template-page.html"},{"code":{"code":"template-md"},"value":"template-page-md.html"},{"code":{"code":"apply-context"},"value":"true"},{"code":{"code":"apply-copyright"},"value":"true"},{"code":{"code":"apply-license"},"value":"true"},{"code":{"code":"fmm-definition"},"value":"http://hl7.org/fhir/versions.html#maturity"},{"code":{"code":"propagate-status"},"value":"true"},{"code":{"code":"excludelogbinaryformat"},"value":"true"}]}}